Company insider dossier

Tilray Inc insider intelligence

TLRY filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Drug Manufacturers - Specialty & Generic Data API
45/100

Balanced insider tape

89/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Latest evidence
6 Aug 2026

Investment committee read

Balanced insider tape

Acquisition and disposal evidence is mixed after low-information compensation and derivative activity is separated out.

Wait for clearer clustering

Evidence in favour

  • 3 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 10 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 06 Aug 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction45Balanced insider tape
Confidence89Deep evidence
Named insiders10participating in the tape
Controlled events13directional common-share events
Acquisition value$69.2Knormalized amount
Disposal value$2.3Mnormalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

17.2013.8010.407.003.60 Acquisition · 6 Aug 2026 · $11.1KAcquisition · 4 Aug 2026 · $46.2KAcquisition · 3 Aug 2026 · $11.9KAcquisition · 30 Jul 2026 · Not reportedAcquisition · 30 Jul 2026 · Not reportedAcquisition · 30 Jul 2026 · Not reportedAcquisition · 30 Jul 2026 · Not reportedDisposal · 30 Jul 2026 · $261.9KDisposal · 30 Jul 2026 · $58.1KDisposal · 30 Jul 2026 · $54.3KDisposal · 30 Jul 2026 · $38.5KAcquisition · 29 Jul 2026 · Not reportedAcquisition · 29 Jul 2026 · Not reportedAcquisition · 29 Jul 2026 · Not reportedAcquisition · 29 Jul 2026 · Not reportedAcquisition · 29 Jul 2026 · Not reportedAcquisition · 29 Jul 2026 · Not reportedAcquisition · 29 Jul 2026 · Not reportedAcquisition · 29 Jul 2026 · Not reportedAcquisition · 29 Jul 2026 · Not reportedAcquisition · 29 Jul 2026 · Not reportedDisposal · 29 Jul 2026 · $906.0KDisposal · 29 Jul 2026 · $198.1KDisposal · 29 Jul 2026 · $184.9KDisposal · 29 Jul 2026 · $120.5KDisposal · 29 Jul 2026 · $86.0KDisposal · 29 Jul 2026 · $86.0KDisposal · 29 Jul 2026 · $86.0KDisposal · 21 Apr 2026 · $232.9K
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
4.57 USD
One-week move
+0.7%
Four-week move
+3.4%
Fair-value gap
-64.7%
Trend signal
Inactive
Relative strength
-54.1

Directional balance

Controlled event mix

23.1%acquisition
Acquisition events
3
Disposal events
10
Net value
-$2.2M

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

025 May
001 Jun
008 Jun
015 Jun
022 Jun
029 Jun
006 Jul
013 Jul
020 Jul
4927 Jul
303 Aug
010 Aug

Named participants

Insider conviction by person

MERTON, CARL AChief Financial Officer553 events
FALTISCHEK, DENISE MChief Strategy Officer533 events
GENDEL, MITCHELLGlobal General Counsel533 events
COHEN, STEVEN MICHAELDirector500 events
LOONEY, THOMAS P.Director500 events
CLANACHAN, DAVID FDirector281 events
HERHALT, JOHANN MICHAELDirector281 events
HOPKINSON, DAVID G.Director281 events
PERSOFSKY, RENAHDirector281 events
SIMON, IRWIN DDirector, President and CEO252 events

Evidence quality

Security and transaction context

Common equity29
Equity compensation24
Options and derivatives0
Other securities0

Role architecture

Who is participating

Director22
Other executive16
Finance leadership8
CEO and chair7

Transaction evidence

Auditable TLRY filing ledger

Showing 1 to 30 of 53.

GENDEL, MITCHELLGlobal General Counsel
AcquisitionCommon equity
2500 sharesCommon Stock
$11.1KDirectional evidence
MERTON, CARL AChief Financial Officer
AcquisitionCommon equity
10000 sharesCommon Stock
$46.2KDirectional evidence
FALTISCHEK, DENISE MChief Strategy Officer
AcquisitionCommon equity
2500 sharesCommon Stock
$11.9KDirectional evidence
FALTISCHEK, DENISE MChief Strategy Officer
AcquisitionCommon equity
26120 sharesCommon Stock
Not reportedContext evidence
FALTISCHEK, DENISE MChief Strategy Officer
DisposalEquity compensation
26120 sharesRestricted Stock Units
Not reportedContext evidence
GENDEL, MITCHELLGlobal General Counsel
DisposalEquity compensation
24379 sharesRestricted Stock Units
Not reportedContext evidence
GENDEL, MITCHELLGlobal General Counsel
AcquisitionCommon equity
24379 sharesCommon Stock
Not reportedContext evidence
HERHALT, JOHANN MICHAELDirector
AcquisitionEquity compensation
62657 sharesRestricted Stock Units
Not reportedContext evidence
HOPKINSON, DAVID G.Director
AcquisitionEquity compensation
62657 sharesRestricted Stock Units
Not reportedContext evidence
LOONEY, THOMAS P.Director
AcquisitionEquity compensation
62657 sharesRestricted Stock Units
Not reportedContext evidence
MERTON, CARL AChief Financial Officer
AcquisitionCommon equity
16656 sharesCommon Stock
Not reportedContext evidence
MERTON, CARL AChief Financial Officer
DisposalEquity compensation
16656 sharesRestricted Stock Units
Not reportedContext evidence
SIMON, IRWIN DDirector, President and CEO
AcquisitionCommon equity
117647 sharesCommon Stock
Not reportedContext evidence
SIMON, IRWIN DDirector, President and CEO
DisposalEquity compensation
117647 sharesRestricted Stock Units
Not reportedContext evidence
SIMON, IRWIN DDirector, President and CEO
DisposalCommon equity
62353 sharesCommon Stock
$261.9KDirectional evidence
FALTISCHEK, DENISE MChief Strategy Officer
DisposalCommon equity
13844 sharesCommon Stock
$58.1KDirectional evidence
GENDEL, MITCHELLGlobal General Counsel
DisposalCommon equity
12921 sharesCommon Stock
$54.3KDirectional evidence
MERTON, CARL AChief Financial Officer
DisposalCommon equity
9161 sharesCommon Stock
$38.5KDirectional evidence
CLANACHAN, DAVID FDirector
DisposalEquity compensation
43104 sharesRestricted Stock Units
Not reportedContext evidence
CLANACHAN, DAVID FDirector
AcquisitionEquity compensation
62657 sharesRestricted Stock Units
Not reportedContext evidence
CLANACHAN, DAVID FDirector
AcquisitionCommon equity
43104 sharesCommon Stock
Not reportedContext evidence
COHEN, STEVEN MICHAELDirector
AcquisitionCommon equity
43104 sharesCommon Stock
Not reportedContext evidence
COHEN, STEVEN MICHAELDirector
DisposalEquity compensation
43104 sharesRestricted Stock Units
Not reportedContext evidence
COHEN, STEVEN MICHAELDirector
AcquisitionEquity compensation
62657 sharesRestricted Stock Units
Not reportedContext evidence
FALTISCHEK, DENISE MChief Strategy Officer
AcquisitionEquity compensation
281901 sharesRestricted Stock Units
Not reportedContext evidence
FALTISCHEK, DENISE MChief Strategy Officer
DisposalEquity compensation
93685 sharesRestricted Stock Units
Not reportedContext evidence
FALTISCHEK, DENISE MChief Strategy Officer
AcquisitionCommon equity
93685 sharesCommon Stock
Not reportedContext evidence
GENDEL, MITCHELLGlobal General Counsel
DisposalEquity compensation
87440 sharesRestricted Stock Units
Not reportedContext evidence
GENDEL, MITCHELLGlobal General Counsel
AcquisitionEquity compensation
263108 sharesRestricted Stock Units
Not reportedContext evidence
GENDEL, MITCHELLGlobal General Counsel
AcquisitionCommon equity
87440 sharesCommon Stock
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context